Santa Barbara-based Serimmune issued $1.4 million in convertible promissory notes in June as part of a $7 million capital campaign. Five investors have so far participated in the round, according to filings with the Securities and Exchange Commission. Serimmune’s technology aims to map and catalogue antibodies and the pathogens, allergens and other agents that they…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
